Biotech entity
Of the tracked stories, 2 of 3 also mention FDA, the most common co-covered peer. Coverage clusters in clinical-trial, which accounts for 2 of those 3, with the remainder spread across 1 other category. They are less corroborated than the beat average, carrying 2.3 original sources each against 3.6 for the same window.
Last mentioned: Aug 20, 2026
Entity pulse
Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 67 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Of the tracked stories, 2 of 3 also mention FDA, the most common co-covered peer. Coverage clusters in clinical-trial, which accounts for 2 of those 3, with the remainder spread across 1 other category. They are less corroborated than the beat average, carrying 2.3 original sources each against 3.6 for the same window. The 168-day window averages about 0.1 stories each week. At 7, the average consequence score sits above the same-window beat average of 6.2. We currently track 3 Biotech stories that mention Johns Hopkins University, published between March 6, 2026 and August 20, 2026.
Computed from the 3 stories linked to this entity, with beat comparisons drawn from all 594 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Johns Hopkins University. Shared-story counts are live from our verified record — not editorial picks.
Trump announces Heidi Overton as FDA Commissioner nominee
President Trump names the White House Domestic Policy Council deputy director to lead the FDA, pending Senate confirmation.
Marty Makary resigns as FDA Commissioner
The previous FDA head leaves behind unfinished projects on ultraprocessed foods, antidepressants, and COVID-19 shots.
Phase 3 Trials
Large-scale multi-site trials aim to provide definitive data for regulatory approval.
SAP Expansion
Canada amends the Special Access Program to include restricted psychedelic substances.
Regulatory Shift
Health Canada begins granting Section 56 exemptions for terminally ill patients.
Foundational Research
Johns Hopkins and NYU publish landmark studies on psilocybin for cancer-related distress.
For biotech and pharma executives, Overton's nomination combines Trump's favored-nation drug pricing push with RFK Jr.'s vaccine skepticism and unfinished reviews of antidepressants and COVID shots. The result could compress margins while opening faster approval pathways for innovation. Investors should watch how she navigates evidence standards and political priorities at the FDA.
Source: MedPage Today · Kstp Television
A landmark study has demonstrated that a single dose of psilocybin, paired with psychological support, significantly outperforms traditional nicotine replacement therapies for long-term smoking cessation. The findings suggest a paradigm shift in treating substance use disorders through psychedelic-assisted therapy.
Emerging clinical research indicates that psilocybin-assisted therapy can significantly alleviate existential dread and depression in terminally ill patients. This development marks a potential paradigm shift in palliative care, moving beyond physical pain management to address deep-seated psychological trauma.
Johns Hopkins University is linked from 3 stories on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
